3-CPs (3-Carbethoxypsoralen) exhibits protective effects against UVB-induced damage in vitro at all tested concentrations; it interferes with antibody-mediated bacterial killing by acting as a capsular polysaccharide of serotype 3, showing approximately 50% inhibition of bacterial killing when 12 ng of purified type 3 CPS is added to the opsonophagocytic killing assay (OPKA); addition of 30 μL of mouse serum collected post-intraperitoneal infection with WU2 (containing 0.4–0.7 μg/mL released type 3 CPS) results in 26% to 52% inhibition of bacterial killing, comparable to the effect of an equivalent amount of purified CPS.